Evidence map›Paper›PMID 40717981›Full record

ArticleFrontiers in pharmacology2025

Shujun Sun, Jie Li, Dingmei Qin, Xiaoxiao Yang, Huilin Zhang, Yue Yang, Mengmeng Li, Ruihua Jin, Jianye Dai, Yong Liu

Abstract read
In one paragraph

Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Evaluation of Immunoprotective Activities of White Button Mushroom (Animals : an open access journal from MDPI · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Shujun SunSchool of Biology and Food Engineering, Fuyang Normal University, Fuyang, China.
Jie LiSchool of Biology and Food Engineering, Fuyang Normal University, Fuyang, China.
Dingmei QinSchool of Biology and Food Engineering, Fuyang Normal University, Fuyang, China.
Xiaoxiao YangSchool of Biology and Food Engineering, Fuyang Normal University, Fuyang, China.
Huilin ZhangSchool of Biology and Food Engineering, Fuyang Normal University, Fuyang, China.
Yue YangSchool of Pharmacy, Lanzhou University, Lanzhou, China.
Mengmeng LiSchool of Biology and Food Engineering, Fuyang Normal University, Fuyang, China.
Ruihua JinFuyang Women and Children's Hospital, Fuyang Normal University, Fuyang, China.
Jianye DaiSchool of Pharmacy, Lanzhou University, Lanzhou, China.
Yong LiuSchool of Biology and Food Engineering, Fuyang Normal University, Fuyang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Preeclampsia stands as a leading cause of maternal mortality. Scutellariae Radix and Atractylodis Macrocephalae Rhizoma (SA) is a commonly employed traditional Chinese medicine pair in the treatment of preeclampsia, yet the underlying mechanisms of their protective effects against preeclampsia remain elusive. Methods: In this study, the N- nitro-L-arginine methyl ester (L-NAME) was utilized to establish a preeclamptic pregnant mouse model, and the protective effects of SA were systematically evaluated. A comprehensive approach integrating network pharmacology analysis, quantitative proteomics, and in vitro experiments was adopted to probe into the relevant mechanisms. Results: It was demonstrated that SA could significantly ameliorate the systolic blood pressure, urinary protein levels, and pathological damage in the kidneys and placenta of mice. Moreover, in vitro experiments further validated the promoting effects of SA, baicalin, and atractylenolide I on the proliferation and migration of HTR-8/SVneo cells. Baicalin and atractylenolide I are the main active and quality control components of SA. Network pharmacology analysis, quantitative proteomics and molecular docking revealed that the PI3K/Akt pathway is a potential mechanism through which SA alleviates preeclampsia. Further investigations showed that SA could reverse L-NAME-induced inhibition of the PI3K/p-Akt/Akt signaling pathway, upregulating eNOS expression and ultimately alleviating vasoconstriction and other preeclampsia-related symptoms. Conclusion: SA has the capacity to improve preeclampsia-induced increases in blood pressure and urinary protein, holding promise as a novel strategy for the treatment of preeclampsia.

Indexed as

atractylodis macrocephalae rhizomadrug pairsPI3K/Akt/eNOS pathwaypreeclampsiascutellariae radix

Identifiers

PMID40717981
PMCPMC12290292

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.